Liraglutide: Uses, Doses, Side Effects, and How It Compares to Semaglutide and Tirzepatide

What Is Liraglutide and How Does It Work?

Liraglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) that shares 97% amino-acid sequence identity with the endogenous hormone. Injected once daily, it binds GLP-1 receptors in the pancreas, brain, gut, and heart to slow gastric emptying, suppress appetite, and stimulate glucose-dependent insulin secretion. Its half-life of roughly 13 hours makes once-daily dosing practical, separating it from shorter-acting exenatide while falling short of the week-long half-life of semaglutide.

GLP-1 receptors in the hypothalamus reduce caloric intake by signaling satiety. In the pancreatic beta cell, liraglutide amplifies insulin release only when blood glucose is elevated, which limits hypoglycemia risk compared with sulfonylureas. In the gut, delayed gastric emptying slows glucose absorption and contributes to the nausea that many patients experience early in treatment.

The drug is supplied as a 6 mg/mL prefilled pen. For Saxenda (the obesity formulation), each pen delivers 18 mg of liraglutide across 30 days at the 3.0 mg maintenance dose. FDA prescribing information for Saxenda specifies that patients who cannot tolerate the 3.0 mg dose after titration should discontinue therapy, because efficacy at lower doses is meaningfully reduced. [1]

FDA-Approved Indications and Doses

Liraglutide carries three distinct FDA approvals across its two formulations.

Victoza (1.2 mg and 1.8 mg) is approved for glycemic control in adults and children aged 10 and older with type 2 diabetes, as an adjunct to diet and exercise. A 0.6 mg/day starter dose is used for one week to minimize gastrointestinal (GI) side effects before titrating to 1.2 mg; the 1.8 mg dose is available for additional glycemic benefit. Victoza also carries an indication to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease, based on the LEADER trial data. [2]

Saxenda (3.0 mg) is approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. A pediatric indication was added in 2020 for adolescents aged 12 to 17 with obesity (body weight above 60 kg).

The Saxenda titration schedule:

• Week 1: 0.6 mg/day
• Week 2: 1.2 mg/day
• Week 3: 1.8 mg/day
• Week 4: 2.4 mg/day
• Week 5 onward: 3.0 mg/day (target maintenance dose)

Patients should be evaluated after 16 weeks. Those who have not lost at least 4% of baseline body weight are unlikely to achieve clinically meaningful results and should discontinue treatment, per the FDA label. [1]

Weight-Loss Efficacy: What the Clinical Trials Show

The SCALE Obesity and Prediabetes trial (N=3,731) remains the landmark efficacy study for Saxenda. At 56 weeks, liraglutide 3.0 mg produced a mean weight loss of 8.4 kg (8.0% body weight) versus 2.8 kg (2.6%) with placebo. Roughly 63% of liraglutide-treated patients lost at least 5% of body weight, compared with 27% on placebo. [3]

Those numbers look modest beside newer agents. STEP-1 (N=1,961) showed semaglutide 2.4 mg producing 14.9% mean weight loss at 68 weeks versus 2.4% placebo (P<0.001). [4] SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg achieving 20.9% mean weight loss at 72 weeks. [5]

The most direct comparison between liraglutide and semaglutide came from the STEP-8 trial (N=338 to 68 weeks, JAMA 2022). Semaglutide 2.4 mg produced a mean weight loss of 15.8% versus 6.4% for liraglutide 3.0 mg, a difference of 9.4 percentage points (95% CI 7.5 to 11.3, P<0.001). [6] At least 10% weight loss was achieved by 70.9% of semaglutide participants compared with 25.6% of liraglutide participants.

The table below organizes the head-to-head data across the GLP-1 class in a single decision framework:

| Agent | Trial | Duration | Mean % Weight Loss | |---|---|---|---| | Liraglutide 3.0 mg | SCALE | 56 weeks | ~8% | | Semaglutide 2.4 mg | STEP-1 | 68 weeks | 14.9% | | Tirzepatide 15 mg | SURMOUNT-1 | 72 weeks | 20.9% | | Retatrutide 12 mg | Phase 2 (NEJM 2023) | 48 weeks | ~24% |

These figures are not interchangeable across trials because populations, placebo arms, and titration schedules differ. They provide directional context, not definitive rankings.

Liraglutide for Type 2 Diabetes: Glycemic and Cardiovascular Outcomes

For type 2 diabetes management, Victoza lowers HbA1c by approximately 1.0 to 1.5 percentage points from baseline at 1.8 mg, with the exact reduction depending on baseline HbA1c and concomitant therapy. [2]

The LEADER trial (N=9,340) assigned adults with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg or placebo for a median of 3.8 years. Liraglutide reduced the rate of the primary MACE outcome (cardiovascular death, nonfatal MI, nonfatal stroke) by 13% relative to placebo (HR 0.87; 95% CI 0.78 to 0.97; P=0.01 for superiority). Cardiovascular death was reduced by 22%. [2]

The American Association of Clinical Endocrinology (AACE) 2022 guidelines state that GLP-1 receptor agonists with demonstrated cardiovascular benefit, including liraglutide, should be prioritized over other glucose-lowering agents in patients with atherosclerotic cardiovascular disease regardless of baseline HbA1c. [7] That recommendation positions Victoza as more than a glycemic tool.

SELECT (N=17,604, semaglutide 2.4 mg, NEJM 2023) subsequently demonstrated a 20% reduction in MACE with semaglutide in people with overweight or obesity without diabetes. [8] No equivalent obesity-dose cardiovascular outcomes trial has been completed for liraglutide.

Liraglutide vs. Semaglutide: A Detailed Comparison

Semaglutide and liraglutide share a mechanism but differ in nearly every clinically relevant parameter.

Dosing schedule. Liraglutide requires daily injection; semaglutide (Ozempic, Wegovy) is injected once weekly. Adherence tends to be higher with weekly regimens in real-world observational data. Oral semaglutide (Rybelsus, 7 mg or 14 mg daily) offers a pill alternative that liraglutide cannot match.

Efficacy. STEP-8 settles the head-to-head question: semaglutide 2.4 mg outperforms liraglutide 3.0 mg by 9.4 percentage points in weight reduction over 68 weeks. [6]

Cardiovascular data. Liraglutide (LEADER) and semaglutide (LEADER equivalent: SUSTAIN-6, plus SELECT for the obesity dose) both carry MACE-reduction data, but SELECT's scope, covering people without diabetes at baseline, is broader.

Cost and access. Without insurance, Saxenda lists at roughly $1,400 per month at the 3.0 mg dose, while Wegovy lists at approximately $1,350 per month. Neither price advantage is decisive, but compounded semaglutide formulations (where available) can substantially undercut both. Liraglutide does not currently appear on FDA shortage lists in the same way semaglutide has, which occasionally makes it more reliably stocked at retail pharmacies.

Tolerability. GI side effects are qualitatively similar. STEP-8 reported nausea in 46% of semaglutide participants versus 35% of liraglutide participants. Higher nausea with semaglutide may reflect its greater potency at the GLP-1 receptor rather than a safety disadvantage per se.

Liraglutide vs. Tirzepatide

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist, giving it a second incretin pathway that liraglutide lacks entirely.

SURMOUNT-1 showed tirzepatide 15 mg achieving 20.9% weight loss at 72 weeks, compared with liraglutide's 8% at 56 weeks in SCALE. [5, 3] No direct randomized head-to-head trial between liraglutide and tirzepatide exists, but the indirect margin exceeds 12 percentage points, making tirzepatide the stronger agent for weight reduction by a wide margin.

For type 2 diabetes, SURPASS-2 compared tirzepatide directly to semaglutide 1 mg and showed tirzepatide 15 mg reducing HbA1c by 2.58 percentage points versus 1.86 for semaglutide. Liraglutide has not been directly tested against tirzepatide in glycemic control trials, but extrapolating from its 1.0 to 1.5 percentage-point HbA1c reduction suggests an even larger gap. [9]

Tirzepatide's weekly dosing and superior efficacy make it the preferred agent in most obesity-medicine algorithms where insurance covers it. The Zepbound FDA label (tirzepatide 2.5 mg to 15 mg for obesity) specifies the same BMI thresholds as Saxenda. [10]

Liraglutide vs. Dulaglutide

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes and cardiovascular risk reduction (REWIND trial). It is not FDA-approved for chronic weight management as a primary indication.

In head-to-head glycemic trials, dulaglutide 1.5 mg and liraglutide 1.8 mg produce broadly similar HbA1c reductions of approximately 1.1 to 1.4 percentage points, though some meta-analyses slightly favor liraglutide at its 1.8 mg dose. The weekly dosing of dulaglutide offers a convenience advantage, and its fixed-dose auto-injector pen requires no manual dialing, which some patients find easier. Weight loss with dulaglutide (approximately 1.5 to 3 kg at 26 weeks) is lower than with liraglutide 1.8 mg (approximately 2 to 3 kg). For patients prioritizing both glycemic control and meaningful weight reduction, liraglutide 1.8 mg holds a slight edge over dulaglutide at standard doses. [11]

Liraglutide vs. Retatrutide

Retatrutide is an investigational triple receptor agonist (GIP, GLP-1, and glucagon receptors) that has not yet received FDA approval. Phase 2 data (N=338, NEJM 2023) showed the 12 mg dose achieving approximately 24.2% weight loss at 48 weeks, with some participants exceeding 30% body-weight reduction by week 48. [12] Compared with liraglutide's 8% at 56 weeks, the magnitude of difference is striking.

Liraglutide's single-receptor mechanism produces the least weight loss of any agent in this class. Retatrutide, if approved, would sit at the opposite end of the spectrum. For patients who need maximum weight reduction, liraglutide is unlikely to be the right tool once retatrutide clears regulatory review.

Side Effects and Safety Considerations

The most common adverse effects of liraglutide are GI: nausea (28 to 40%), diarrhea (17%), vomiting (11%), constipation (10%), and dyspepsia. Most symptoms peak during the first 4 to 8 weeks and resolve as the body adapts to slower gastric emptying. Titrating slowly, eating smaller portions, and avoiding high-fat meals at the time of injection all reduce GI burden. [1]

Serious but less common risks:

• Thyroid C-cell tumors. Liraglutide caused dose-dependent and duration-dependent thyroid C-cell tumors in rodents. The clinical relevance in humans is unknown, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). [1]
• Pancreatitis. Acute pancreatitis has been reported. Patients with a history of pancreatitis should not use liraglutide.
• Gallbladder disease. Weight loss itself increases cholelithiasis risk. Saxenda's label notes a higher rate of gallbladder-related events in treated patients versus placebo.
• Heart rate. Liraglutide increases mean resting heart rate by approximately 2 to 3 beats per minute. Clinicians should monitor patients with pre-existing tachyarrhythmias.
• Hypoglycemia. Rare when used as monotherapy, but risk rises when combined with insulin or sulfonylureas.

The FDA mandates a Risk Evaluation and Mitigation Strategy (REMS) for Saxenda that includes a medication guide for patients and a counseling plan regarding the thyroid tumor risk.

Who Is a Good Candidate for Liraglutide in 2025?

Given the superior efficacy of semaglutide and tirzepatide, liraglutide's role has narrowed but remains real. Specific clinical scenarios where liraglutide may be preferred include:

1. Patients who have already tried once-weekly GLP-1 agents and experienced intolerable GI side effects at higher doses. The shorter half-life of liraglutide means side effects clear more rapidly if the drug is stopped or the dose is reduced.
2. Adolescents with obesity aged 12 to 17. Saxenda is the only GLP-1 approved in this age group for weight management at the time of writing; Wegovy received an adolescent approval in 2023, so this advantage has largely closed.
3. Patients needing a cardiovascular risk reduction signal in type 2 diabetes where cost or weekly injection adherence is a barrier to semaglutide or dulaglutide.
4. Cost-constrained patients where a manufacturer coupon or insurance formulary placement makes liraglutide the most accessible option.

The AACE/ACE obesity clinical practice guidelines recommend that pharmacotherapy for obesity should be initiated as an adjunct to lifestyle modification, and that the choice of agent should account for comorbidities, cost, tolerability, and efficacy goals. [7] Liraglutide meets that bar for a meaningful subset of patients even as newer agents expand the treatment menu.

Starting Liraglutide: Practical Clinical Guidance

Prescribers should confirm the following before starting:

• BMI eligibility (30 or above for Saxenda; 27 or above with comorbidity; diabetes diagnosis for Victoza)
• Rule out MEN2 or personal/family history of medullary thyroid carcinoma
• Confirm no active or recent pancreatitis
• Review concomitant insulin or sulfonylurea use and adjust doses preemptively to reduce hypoglycemia risk
• Establish baseline weight, HbA1c, lipid panel, and liver enzymes

The injection is given subcutaneously in the abdomen, thigh, or upper arm. Rotation of injection sites prevents lipohypertrophy. The pen may be stored at room temperature (below 30°C / 86°F) for up to 30 days after first use; unused pens should be refrigerated. [1]

Patients should be counseled that liraglutide is not a standalone therapy. The SCALE trial required structured dietary and exercise counseling in both arms. Weight loss outcomes in clinical practice without behavioral support are lower than trial figures, a gap that applies equally to semaglutide and tirzepatide.